Literature DB >> 8613365

Molecular composition of Clostridium botulinum type A progenitor toxins.

K Inoue1, Y Fujinaga, T Watanabe, T Ohyama, K Takeshi, K Moriishi, H Nakajima, K Inoue1, K Oguma.   

Abstract

The molecular composition of progenitor toxins produced by a Clostridium botulinum type A strain (A-NIH) was analyzed. The strain produced three types of progenitor toxins (19 S, 16 S, and 12 S) as reported previously. Purified 19 S and 16 S toxins demonstrated the same banding profiles on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), indicating that they consist of the same protein components. The nontoxic components of the 19 S and 16 S toxins are a nontoxic non-hemagglutinin (HA) (molecular mass, 120 kDa) and HA. HA could be fractionated into five subcomponents with molecular masses of 52, 35, 20, 19, and 15 kDa in the presence of 2-mercaptoethanol. The molar ratios of neurotoxins, nontoxic non-HAs, and each HA subcomponent of the 19 S and 16 S toxins showed that only HA-35 of the 19 S toxin was approximately twice the size of that of the 16 S toxin, suggesting that the 19 S toxin is a dimer of the 16 S toxin cross-linked by the 35-kDa subcomponent. The nontoxic non-HA of the 12 S toxin, but not those of the 19 S and 16 S toxins, demonstrated two bands with molecular masses of 106 and 13 kDa on SDS-PAGE with or without 2-mercaptoethanol. It was concluded from the N-terminal amino acid sequences that 106- and 13-kDa proteins were generated by a cleavage of whole nontoxic non-HA. This may explain why the 12 S and 16 S (and 19 S) toxins exist in the same culture. We also found that the HA and its 35-kDa subcomponent exist in a free state in the culture fluid along with three types of progenitor toxins.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8613365      PMCID: PMC173966          DOI: 10.1128/iai.64.5.1589-1594.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  17 in total

1.  Clostridium botulinum types A, B, C1, and E produce proteins with or without hemagglutinating activity: do they share common amino acid sequences and genes?

Authors:  E Somers; B R DasGupta
Journal:  J Protein Chem       Date:  1991-08

2.  A new method for the large-scale production of high-titre botulinum formol-toxoid types C and D.

Authors:  M STERNE; L M WENTZEL
Journal:  J Immunol       Date:  1950-08       Impact factor: 5.422

3.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

4.  A common subunit structure in Clostridium botulinum type A, B and E toxins.

Authors:  B R DasGupta; H Sugiyama
Journal:  Biochem Biophys Res Commun       Date:  1972-07-11       Impact factor: 3.575

5.  Molecular characterization of two forms of nontoxic-nonhemagglutinin components of Clostridium botulinum type A progenitor toxins.

Authors:  R Fujita; Y Fujinaga; K Inoue; H Nakajima; H Kumon; K Oguma
Journal:  FEBS Lett       Date:  1995-11-27       Impact factor: 4.124

6.  Molecular construction of Clostridium botulinum type C progenitor toxin and its gene organization.

Authors:  Y Fujinaga; K Inoue; S Shimazaki; K Tomochika; K Tsuzuki; N Fujii; T Watanabe; T Ohyama; K Takeshi; K Inoue
Journal:  Biochem Biophys Res Commun       Date:  1994-12-15       Impact factor: 3.575

7.  The complete nucleotide sequence of the gene coding for the nontoxic-nonhemagglutinin component of Clostridium botulinum type C progenitor toxin.

Authors:  K Tsuzuki; K Kimura; N Fujii; N Yokosawa; K Oguma
Journal:  Biochem Biophys Res Commun       Date:  1992-03-31       Impact factor: 3.575

8.  Botulinum neurotoxin type A: sequence of amino acids at the N-terminus and around the nicking site.

Authors:  B R DasGupta; M L Dekleva
Journal:  Biochimie       Date:  1990-09       Impact factor: 4.079

9.  Characterization of nontoxic-nonhemagglutinin component of the two types of progenitor toxin (M and L) produced by Clostridium botulinum type D CB-16.

Authors:  T Ohyama; T Watanabe; Y Fujinaga; K Inoue; H Sunagawa; N Fujii; K Inoue; K Oguma
Journal:  Microbiol Immunol       Date:  1995       Impact factor: 1.955

10.  Separation and characterization of heavy and light chains from Clostridium botulinum type C toxin and their reconstitution.

Authors:  B Syuto; S Kubo
Journal:  J Biol Chem       Date:  1981-04-25       Impact factor: 5.157

View more
  54 in total

1.  Molecular cloning of an apoptosis-inducing protein, pierisin, from cabbage butterfly: possible involvement of ADP-ribosylation in its activity.

Authors:  M Watanabe; T Kono; Y Matsushima-Hibiya; T Kanazawa; N Nishisaka; T Kishimoto; K Koyama; T Sugimura; K Wakabayashi
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

2.  Purification of fully activated Clostridium botulinum serotype B toxin for treatment of patients with dystonia.

Authors:  Hideyuki Arimitsu; Kaoru Inoue; Yoshihiko Sakaguchi; Jaechul Lee; Yukako Fujinaga; Toshihiro Watanabe; Tohru Ohyama; Robert Hirst; Keiji Oguma
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

3.  Accumulation of Clostridium perfringens epsilon-toxin in the mouse kidney and its possible biological significance.

Authors:  Eiji Tamai; Tetsuya Ishida; Shigeru Miyata; Osamu Matsushita; Hirofumi Suda; Shoji Kobayashi; Hiroshi Sonobe; Akinobu Okabe
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

4.  The case of botulinum toxin in milk: experimental data.

Authors:  Oliver G Weingart; Tanja Schreiber; Conny Mascher; Diana Pauly; Martin B Dorner; Thomas F H Berger; Charlotte Egger; Frank Gessler; Martin J Loessner; Marc-Andre Avondet; Brigitte G Dorner
Journal:  Appl Environ Microbiol       Date:  2010-04-02       Impact factor: 4.792

Review 5.  Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Authors:  S Ramasamy; C Q Liu; H Tran; A Gubala; P Gauci; J McAllister; T Vo
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

6.  Crystallization and preliminary X-ray analysis of the HA3 component of Clostridium botulinum type C progenitor toxin.

Authors:  Toshio Nakamura; Takashi Tonozuka; Mao Kotani; Kanae Obata; Keiji Oguma; Atsushi Nishikawa
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-11-21

7.  Composition and molecular size of Clostridium botulinum Type A toxin-hemagglutinin complex.

Authors:  Andy Pickett; Karen Perrow
Journal:  Protein J       Date:  2009-06       Impact factor: 2.371

Review 8.  Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review.

Authors:  Todd A Linsenmeyer
Journal:  J Spinal Cord Med       Date:  2013-09       Impact factor: 1.985

9.  A Phase III Study of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines.

Authors:  Matthias Imhof; Ulrich Kühne
Journal:  J Clin Aesthet Dermatol       Date:  2011-10

10.  Differentiation of the gene clusters encoding botulinum neurotoxin type A complexes in Clostridium botulinum type A, Ab, and A(B) strains.

Authors:  Giovanna Franciosa; Francesca Floridi; Antonella Maugliani; Paolo Aureli
Journal:  Appl Environ Microbiol       Date:  2004-12       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.